Buy Boston Scientific

Logo for stock BSX (Boston Scientific)

Amount

£
GBP

Latest price

$105.56
(£1.00 = $1.242)

Number of shares (est.)

0

Start investing today

Open an investment account in Emma and enjoy commission free stock trading. Capital at risk, other charges apply.

QR code linking to downloads for the Emma app.
Download on the App Store buttonGet it on Google Play button

Metrics

Market Cap

$156.491B

P/E ratio

85.14

EPS

$1.247

Beta

0.77

Dividend rate

N/A

Dividend yield

N/A

About

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. Its MedSurg segment includes Endoscopy, Urology and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with less invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. Its Interventional Cardiology Therapies business develops and manufactures technologies for diagnosing and treating coronary artery disease and aortic valve conditions. It also owns the transcarotid artery revascularization (TCAR) platform.

CEO

Mr. Michael F. (Mike) Mahoney

Employees

N/A

Sector

Health

Company HQ

MARLBOROUGH, United States of America

News

Logo for news article #0 (The Zacks Analyst Blog The Procter & Gamble, Boston, ConocoPhillips and Kewaunee Scientific)

The Zacks Analyst Blog The Procter & Gamble, Boston, ConocoPhillips and Kewaunee Scientific

The Procter & Gamble, Boston, ConocoPhillips and Kewaunee Scientific are included in this Analyst Blog.

Zacks Investment Research

February 11, 2025

Logo for news article #1 (Best Momentum Stocks to Buy for February 10th)

Best Momentum Stocks to Buy for February 10th

BSX, ENVA and CFR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 10, 2025.

Zacks Investment Research

February 10, 2025

Logo for news article #2 (5 Momentum Stocks to Buy for February Amid Volatility)

5 Momentum Stocks to Buy for February Amid Volatility

These five stocks have strong momentum for February. These are: APH, BSX, NLY, PNFP, FHN.

Zacks Investment Research

February 10, 2025

Emma logo
Facebook logoTiktok logoTwitter / X logoInstagram logo

© 2025 Emma Technologies Ltd. All Rights Reserved.

Emma is registered and incorporated in England and Wales.

Emma Technologies Ltd is an appointed representative of RiskSave Technologies Ltd, which is authorised and regulated by the Financial Conduct Authority (FRN 775330).

Payment services (Non MIFID or Deposit related products) for Emma Technologies Ltd are provided by The Currency Cloud Limited. Registered in England No. 06323311. Registered Office: Stewardship Building 1st Floor, 12 Steward Street London E1 6FQ. The Currency Cloud Limited is authorised by the Financial Conduct Authority under the Electronic Money Regulations 2011 for the issuing of electronic money (FRN: 900199). For more detail on how your money is protected please see here. You can also find Currency Cloud's Terms of Use here.

Emma Technologies Ltd is an Introducer Appointed Representative of Quint Group Limited, which is authorised and regulated by the Financial Conduct Authority (FRN 669450). Emma Technologies Ltd is not a lender. Emma Technologies Ltd introduces customers to Monevo Limited who is a licensed credit broker.

Emma is registered with the Financial Conduct Authority under the Payment Services Regulations 2017 for the provision of payment services.

Financial Conduct Authority Reg Nr: 794952.
Company Registration Number: 10578464.
Data Protection Registration Number: ZA241546.

All testimonials, reviews, opinions or case studies presented on our website may not be indicative of all customers. Results may vary and customers agree to proceed at their own risk.